Avalo Therapeutics, Inc. (AVTX) Balance Sheet

The $490.8M in total assets, up from $99.9M in the prior quarter, reflects a substantial equity infusion, likely from a public offering following the positive Phase 2 results. This reverses a trend of declining assets from $150.7M in Q4 2024 to $99.9M in Q1 2026, which was driven by cash burn and operating losses. The equity base expanded from $68.3M to $448.7M, suggesting the company has secured a multi-year runway, but the accumulated deficit of -$504.5M indicates the balance sheet remains heavily dependent on external capital.

Total debt of $242K is immaterial, and the D/E ratio of 0.00 indicates no traditional leverage. However, the company's history of frequent equity raises, as evidenced by the jump in equity from $68.3M to $448.7M in one quarter, implies that shareholders bear the burden of financing. The lack of debt provides flexibility, but the need for future capital to fund Phase 3 trials may lead to further dilution, which is a key risk for existing shareholders.

Cash of $85.4M represents 17% of total assets, while goodwill of $10.5M is unchanged, indicating no impairment. PPE is minimal at $288K, confirming a virtual asset-light model. The balance sheet is essentially a cash container for funding R&D, with the real assets being the clinical pipeline, which is not reflected on the balance sheet. This suggests that the book value is not a meaningful indicator of the company's intrinsic value, which depends on clinical success.

The equity increase is entirely due to new capital raises, not retained earnings, as the accumulated deficit grew from -$468.2M to -$504.5M in the quarter. This implies that the company is still burning cash at a rapid pace, and the new capital will be consumed by R&D expenses. The reliance on external equity rather than internal generation highlights the pre-revenue stage and the need for successful clinical development to create value.

The current ratio of 19.31 indicates a strong short-term liquidity position, and cash of $85.4M provides a significant buffer. However, given the prior quarter's operating loss of $31.5M, the cash runway is approximately 2.7 quarters if burn remains at that level, though the capital raise may have been sized to fund Phase 3 trials. The high current ratio is a positive sign, but the sustainability depends on controlling burn and achieving clinical milestones.